Allergy Therapeutics plc’s (AGY) Buy Rating Reiterated at Panmure Gordon
A number of other equities research analysts also recently issued reports on the stock. Numis Securities Ltd reaffirmed a buy rating and set a GBX 45 ($0.61) price target on shares of Allergy Therapeutics plc in a research note on Friday, September 22nd. FinnCap reiterated a buy rating and set a GBX 46 ($0.62) price objective on shares of Allergy Therapeutics plc in a research report on Thursday, August 24th.
Shares of Allergy Therapeutics plc (AGY) opened at 33.00 on Thursday. The firm’s market cap is GBX 196.06 million. Allergy Therapeutics plc has a 52 week low of GBX 19.00 and a 52 week high of GBX 34.00. The firm has a 50-day moving average of GBX 29.82 and a 200 day moving average of GBX 27.76.
Allergy Therapeutics plc Company Profile
Allergy Therapeutics Plc is a pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum-free products. The Company’s segments are Central Europe, which includes segments, such as Germany, Australia, Switzerland and the Netherlands; Southern Europe, which includes Italy and Spain; the United Kingdom, and Rest of World.
Receive News & Stock Ratings for Allergy Therapeutics plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics plc and related stocks with our FREE daily email newsletter.